Vertex Pharmaceuticals Incorporated
VRTXNASDAQHealthcare● Active
$447.35
+$0.52(+0.12%)
Market Cap$113.5B
P/E Ratio—
52W High$507.92
52W Low$362.5
Vertex Pharmaceuticals Incorporated (VRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VRTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $12.07B | $11.02B | $9.87B | $8.93B | $7.57B |
| Cost of Revenue | $1.81B | $1.53B | $1.26B | $1.08B | $0.90B |
| Gross Profit | $10.27B | $9.49B | $8.61B | $7.85B | $6.67B |
| Gross Margin %(computed) | 85.03% | 86.11% | 87.21% | 87.90% | 88.06% |
| Operating Expenses | |||||
| R&D Expenses | $3.75B | $3.63B | $3.16B | $2.66B | $3.05B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $5.51B | $9.72B | $4.78B | $3.54B | $3.89B |
| Operating Income | $4.76B | ($0.23B) | $3.83B | $4.31B | $2.78B |
| Operating Margin %(computed) | 39.43% | -2.11% | 38.83% | 48.23% | 36.73% |
| Interest Income | $0.49B | $0.60B | $0.61B | $0.14B | $0.00B |
| Interest Expense | $0.01B | $0.03B | $0.04B | $0.05B | $0.06B |
| Income Before Tax | $4.64B | $0.25B | $4.38B | $4.23B | $2.73B |
| Income Tax Expense | $0.69B | $0.78B | $0.76B | $0.91B | $0.39B |
| Net Income | $3.95B | ($0.54B) | $3.62B | $3.32B | $2.34B |
| Net Margin %(computed) | 32.74% | -4.86% | 36.68% | 37.20% | 30.92% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $15.46 | $-2.08 | $14.05 | $12.97 | $9.09 |
| Wtd Avg Shares | 0.26B | 0.26B | 0.26B | 0.26B | 0.26B |
| EBITDA | $4.97B | $0.49B | $4.61B | $4.44B | $2.92B |
| EBITDA Margin %(computed) | 41.14% | 4.41% | 46.66% | 49.67% | 38.52% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Vertex Pharmaceuticals Incorporated data
About Vertex Pharmaceuticals Incorporated (VRTX) Income Statement
Vertex Pharmaceuticals Incorporated (VRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, VRTX reported revenue of $12.07B, gross profit of $10.27B (gross margin 85.03%), and net income of $3.95B — a net profit margin of 32.74%.
Frequently asked questions
VRTX · 4 questionsVertex Pharmaceuticals Incorporated (VRTX) reported revenue of $12.07B for 2025, up 9.6% year-over-year.
VRTX revenueVRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08